Diethylstilbestrol (DES) linked to cancer of the cervix or vagina.

Diethylstilbestrol (DES) is a synthetic estrogen that was developed in the late 1930s and prescribed to pregnant women in the United States from the 1940s through the 1970s to prevent miscarriages and other pregnancy complications. It was later discovered that DES was ineffective for this purpose and was associated with serious health risks for both the women who took it and their children.

DES is now recognized as a potent endocrine disruptor and a known carcinogen, and it has been linked to a range of adverse health effects, including an increased risk of certain cancers, infertility, and other reproductive problems. Children who were exposed to DES in utero may also be at increased risk for developmental and neurological problems.

In response to the health risks associated with DES, the U.S. Food and Drug Administration (FDA) banned its use in pregnancy in 1971, and subsequent research has led to stricter regulations of pharmaceuticals and increased emphasis on safety and efficacy testing before new drugs are approved.

DES is an important example of the risks associated with the use of pharmaceuticals and the importance of ongoing monitoring and evaluation of healthcare interventions to ensure that they are safe and effective.

MedHelpCenter.us recommends that you call the Senior Health Insurance Agency at 813-592-8568 for further explanation.